Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, Inc., has reinforced its early stage topical and semi-solids capability by investing in a Becomix homogenizer mixer. The installation and validation of the new equipment extends the company's ability to manufacture creams, ointments, and semi-solids to support clients' clinical trial needs and enables it to efficiently deal with more complex formulations. Used primarily for the production of topical drug products, the Becomix RW30 model homogenizer gives the contract development and manufacturing organization (CDMO) the scalability to now supply products for Phase III studies. The move by Juniper Pharma Services to make a significant investment into its topical and semi-solids equipment follows an increase in demand from its clients for development, processing scale-up, and clinical manufacture.